Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Edler

Showing results (61-70 of 122) with videos related to

Pageof 13
Sort By:
International Journal of Cancer|June 15, 1983
Spontaneous in vitro malignant transformation in a xeroderma pigmentosum fibroblast lineH W Thielmann, E Fischer, R T Dzarlieva, et al.
Acta Crystallographica. Section E, Structure Reports Online|May 18, 2011
(6R)-2-tert-Butyl-6-[(4R,5S)-3-isopropyl-4-methyl-5-phenyl-oxazolidin-2-yl]phenolTakaoki Koyanagi, Kate L Edler, Raleigh W Parrott, et al.
Onkologie|February 1, 1990
[Treatment of advanced pancreatic cancer with 5-fluorouracil, 4-epidoxorubicin and mitomycin C (FEM II). From the Chemotherapy of Gastrointestinal Tumors Group]S Verhees, H Flechtner, W Queisser, et al.
Onkologie|July 7, 2001
Phase I Clinical Trial of a Day-1, -3, -5 Every 3 WeeksPhase I Clinical Trial of Day-1, -3, -5 Every 3 Weeks Schedule with Titanocene Dichloride (MKT 5) in Patients with Advanced Cancer. (Phase I Study Group of the AIO of the German Cancer Society)K. Mross, P. Robben-Bathe, L. Edler, et al.
Onkologie|June 1, 1990
Pirarubicin in advanced non-small cell lung cancer. A trial of the Phase I/II Study Group of the Association for Medical Oncology of the German Cancer SocietyP Drings, I U Günther, U Gatzemeier, et al.
Acta Crystallographica. Section E, Structure Reports Online|May 18, 2011
(6S)-2,4-Di-tert-butyl-6-[(4S,5R)-3-iso-propyl-4-methyl-5-phenyloxazolidin-2-yl]phenolIan Sean Campbell, Kate L Edler, Raleigh W Parrott, et al.
Acta Crystallographica. Section E, Structure Reports Online|May 18, 2011
(6S)-2-tert-Butyl-6-[(4S,5R)-3,4-dimethyl-5-phenyloxazolidin-2-yl]phenolAlexander E Anderson, Kate L Edler, Raleigh W Parrott, et al.
Archives of Dermatological Research|January 1, 1982
Xeroderma pigmentosum patients from Germany: clinical symptoms and DNA repair characteristicsE Fischer, H W Thielmann, B Neundörfer, et al.
Urological Research|January 1, 1995
Tumor induction and prophylaxis following different forms of intestinal urinary diversion in a rat modelT Kälble, K Busse, F Amelung, et al.
Journal of Medical Virology|August 16, 2001
Reduced prevalence of serum antibodies against adeno-associated virus type 2 in patients with adult T-cell leukaemia lymphomaC M Walz, M Nakamura, T Fukunaga, et al.
Pageof 13

Showing results (61-70 of 122) with videos related to

Sort By:
Pageof 13
International Journal of Cancer|June 15, 1983
Spontaneous in vitro malignant transformation in a xeroderma pigmentosum fibroblast lineH W Thielmann, E Fischer, R T Dzarlieva, et al.
Acta Crystallographica. Section E, Structure Reports Online|May 18, 2011
(6R)-2-tert-Butyl-6-[(4R,5S)-3-isopropyl-4-methyl-5-phenyl-oxazolidin-2-yl]phenolTakaoki Koyanagi, Kate L Edler, Raleigh W Parrott, et al.
Onkologie|February 1, 1990
[Treatment of advanced pancreatic cancer with 5-fluorouracil, 4-epidoxorubicin and mitomycin C (FEM II). From the Chemotherapy of Gastrointestinal Tumors Group]S Verhees, H Flechtner, W Queisser, et al.
Onkologie|July 7, 2001
Phase I Clinical Trial of a Day-1, -3, -5 Every 3 WeeksPhase I Clinical Trial of Day-1, -3, -5 Every 3 Weeks Schedule with Titanocene Dichloride (MKT 5) in Patients with Advanced Cancer. (Phase I Study Group of the AIO of the German Cancer Society)K. Mross, P. Robben-Bathe, L. Edler, et al.
Onkologie|June 1, 1990
Pirarubicin in advanced non-small cell lung cancer. A trial of the Phase I/II Study Group of the Association for Medical Oncology of the German Cancer SocietyP Drings, I U Günther, U Gatzemeier, et al.
Acta Crystallographica. Section E, Structure Reports Online|May 18, 2011
(6S)-2,4-Di-tert-butyl-6-[(4S,5R)-3-iso-propyl-4-methyl-5-phenyloxazolidin-2-yl]phenolIan Sean Campbell, Kate L Edler, Raleigh W Parrott, et al.
Acta Crystallographica. Section E, Structure Reports Online|May 18, 2011
(6S)-2-tert-Butyl-6-[(4S,5R)-3,4-dimethyl-5-phenyloxazolidin-2-yl]phenolAlexander E Anderson, Kate L Edler, Raleigh W Parrott, et al.
Archives of Dermatological Research|January 1, 1982
Xeroderma pigmentosum patients from Germany: clinical symptoms and DNA repair characteristicsE Fischer, H W Thielmann, B Neundörfer, et al.
Urological Research|January 1, 1995
Tumor induction and prophylaxis following different forms of intestinal urinary diversion in a rat modelT Kälble, K Busse, F Amelung, et al.
Journal of Medical Virology|August 16, 2001
Reduced prevalence of serum antibodies against adeno-associated virus type 2 in patients with adult T-cell leukaemia lymphomaC M Walz, M Nakamura, T Fukunaga, et al.
Pageof 13